We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+32.42%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$703M
AUM Growth
+$202M
Cap. Flow
+$117M
Cap. Flow %
16.67%
Top 10 Hldgs %
43.13%
Holding
134
New
60
Increased
28
Reduced
13
Closed
31

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$12.9M
2
XRAY icon
Dentsply Sirona
XRAY
+$9.25M
3
BSX icon
Boston Scientific
BSX
+$7.14M
4
VRAY
ViewRay, Inc.
VRAY
+$7.09M
5
GILD icon
Gilead Sciences
GILD
+$6.65M

Top Sells

Rank Stock Value
1
SIBN icon
SI-BONE Inc
SIBN
+$4.49M
2
AMGN icon
Amgen
AMGN
+$3.89M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$3.33M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$2.99M
5
AMRN
Amarin Corp
AMRN
+$2.78M

Sector Composition

Rank Sector Weight
1 Healthcare 36.29%
2 Industrials 0.63%
3 Financials 0.27%
4 Technology 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVRO
126
PUT
DELISTED
NEVRO CORP.
NVRO
– –
-90,000
Closed -$3.5M
ITCI
127
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-27,700
Closed -$316K
MDRX
128
PUT
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-194,400
Closed -$1.87M
CSII
129
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-7,952
Closed -$227K
GBT
130
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-50,000
Closed -$2.05M
RDUS
131
DELISTED
Radius Health, Inc.
RDUS
– –
-57,131
Closed -$942K
ALXN
132
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-34,237
Closed -$3.33M
PTLA
133
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-50,000
Closed -$976K
ACET
134
DELISTED
Aceto Corp
ACET
– –
-704,034
Closed -$591K
2 3 4 5
6

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q1 2019 Portfolio in Review

As of Q1 2019, Pura Vida Investments held 134 positions worth $703M, up 40% from $501M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Pura Vida Investments deployed $117M of net new capital in Q1 2019, opening 60 new positions and adding to 28 existing holdings. Its largest new stake was Zimmer Biomet: 113,300 shares worth $14M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 28% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Tandem Diabetes Care, an estimated $2.99M trimmed.

  • Pura Vida Investments's largest Q1 2019 buy was Zimmer Biomet: 113,300 shares worth $14M.
  • Pura Vida Investments added most to Boston Scientific in Q1 2019, an estimated $7.14M increase.
  • Pura Vida Investments's biggest Q1 2019 reduction was Tandem Diabetes Care, cutting an estimated $2.99M.
  • Pura Vida Investments fully exited SI-BONE Inc in Q1 2019, selling an estimated $4.49M.
  • Pura Vida Investments's ten largest holdings make up 43% of its $703M portfolio in Q1 2019.
  • Pura Vida Investments opened 60 new positions and closed 31 in Q1 2019.
  • Pura Vida Investments's portfolio value rose 40% quarter-over-quarter to $703M.

Based on Pura Vida Investments's 13F filing for Q1 2019, filed 14 May 2019.